R. Stubbs

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Annelot M. Dekker, A. Destée, S. Bates, 2017, The Lancet Neurology.

Non-clinical development of ozanezumab: a humanised antibody targeting the amino terminus of neurite outgrowth inhibitor A (Nogo-A)

R. Prinjha, J. Wuerthner, A. Lynch, 2015 .

Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease

Robert P. Anderson, Glenn O. Brown, A. Coates, 2020, BMC Medicine.

Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten‐free diet

Glenn O. Brown, M. Mäki, B. Lebwohl, 2020 .

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Annelot M. Dekker, A. Destée, S. Bates, 2017, The Lancet Neurology.